



Under the Paperwork Reduction Act of 1995 no Persons are required to respond to a collection of information unless it contains a valid OMR control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/589,841
Filing Date	July 5, 2007
First Named Inventor	Jun Nakayama
Art Unit	1733
Examiner Name	Not Yet Assigned
Attorney Docket Number	BURN1110-1

Sheet

2

of

2

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	AB	ASHIDA et al., "A Novel Endo-Beta-Galactosidase from Clostridium Perfringens That Liberates the Disaccharide GlcNAc α 1-4Gal from Glycans Specifically Expressed in the Gastric Gland Mucous Cell-type Mucin", <i>J. of Biological Chemistry</i> 276(30):28226-28232, 2001.	
	AC	NAKAYAMA et al., "Expression Cloning of a Human Alpha1,4-N-Acetylglucosaminyltransferase that Forms GlcNAc-Alpha-1,4-Gal-Beta-R, a Glycan Specifically Expressed in the Gastric Gland Mucous Cell-Type Mucin", <i>Proc. National Academy of Sciences</i> , 96(16):8991-8996, 1999.	
	AD	SUZUKI et al., "Molecular Cloning and Expression of a Novel Human Beta-Gal-3-O-Sulfotransferase that Acts Preferentially on N-Acetylglucosamine in N- and O-Glycans", <i>J. of Biological Chemistry</i> , 276(26):24388-24395, 2001.	
	AE	UJITA et al., "Synthesis of Poly-N-Acetylglucosamine in Core 2 Branched O-Glycans; The Requirement of Novel Beta-1, 4-Galactosyltransferase IV and Beta-1,3-N-Acetylglucosaminyltransferase", <i>J. of Biological Chemistry</i> , 273(52):34843-34849, 1998.	
	AF	ZHANG et al., "Immunohistochemical Demonstration of Alpha-1,4-N-Acetylglucosaminyltransferase that Forms GlcNAc-Alpha-1,4-Gal-beta Residues in Human Gastrointestinal Mucosa", <i>J. of Histochemistry and Cytochemistry</i> , 49(5):587-596, 2001.	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

